Ovid Therapeutics Stock (NASDAQ:OVID)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$1.14

52W Range

$0.68 - $4.10

50D Avg

$1.15

200D Avg

$2.18

Market Cap

$83.75M

Avg Vol (3M)

$160.97K

Beta

0.39

Div Yield

-

OVID Company Profile


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

40

IPO Date

May 05, 2017

Website

OVID Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21
Related Party-$196.00M
License$1.50M$12.38M

Fiscal year ends in Dec 23 | Currency in USD

OVID Financial Summary


Dec 23Dec 22Dec 21
Revenue$391.69M$1.50M$208.38M
Operating Income$-59.28B$-55.55M$124.21M
Net Income$-52.34B$-51.41M$122.83M
EBITDA$-59.28B$-55.55M$124.45M
Basic EPS$-0.74$-0.73$1.78
Diluted EPS$-0.74$-0.73$1.76

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
NUVBNuvation Bio Inc.
ACHLAchilles Therapeutics plc
NXTCNextCure, Inc.
CTMXCytomX Therapeutics, Inc.
SPROSpero Therapeutics, Inc.
CNTBConnect Biopharma Holdings Limited
ASMBAssembly Biosciences, Inc.
NLTXNeurogene Inc.
TILInstil Bio, Inc.